Expensive Asana stock price could surge by 195% in 2025
Asana stock price has suffered a harsh reversal in the past few days as investors fade the December 5 earnings surge. ASAN shares retreated to $21.65, down by over 22%…
Sprout Social stock is down 77% from ATH: time to buy the dip?
Sprout Social stock price has remained under pressure this year as the company’s growth trajectory slowed. SPT was trading at $32.45, down by over 77.5% from its all-time high, bringing…
As the ZipRecruiter stock price implodes, will it rebound in 2025?
ZipRecruiter (ZIP) stock price has imploded and crashed to a record low as concerns about its growth in a difficult job market continue. It has slipped to an all-time low…
Coursera stock price analysis: will this edtech giant rebound?
Coursera stock price has crashed to a near-record low as the company’s business growth decelerates amid an uptick in AI use. COUR was trading at $8.31, a few points above…
Will the falling Hims & Hers stock price recover in 2025?
Hims & Hers stock price has greatly performed this year as it continued to disrupt the healthcare industry. HIMS has jumped by almost 200% this year, while other companies in…
US inflation cools in November, offering relief amidst Fed concerns
The latest economic data reveals a welcome moderation in inflation, as the personal consumption expenditures (PCE) price index rose by a less-than-expected 0.1% in November. This figure, a notable decrease…
The growing power of the individual investor
Professional investors have long held significant advantages over individual investors. They have vast resources at their disposal, including technology, data, and dedicated teams of market analysts. The prevailing wisdom is…
Novo Nordisk stock just tanked 25%: here’s what happened
Novo Nordisk A/S (CPH: NOVO-B) is being punished this morning after posting a disappointing update related to CagriSema. The pharmaceutical behemoth said its experimental weight-loss treatment helped patients lower their…
Humacyte stock may fail to sustain today’s gains: find out more
Shares of Humacyte Inc (NASDAQ: HUMA) nearly doubled on Friday after receiving full approval for its flagship SYMVESS product from the US Food and Drug Administration (FDA). Regulatory approval for…